Lal S, Nair N P, Cecyre D, Quirion R
McGill Center for Research in Schizophrenia, Douglas Hospital, Verdun, Quebec, Canada.
Acta Psychiatr Scand. 1993 Jun;87(6):380-3. doi: 10.1111/j.1600-0447.1993.tb03391.x.
The receptor binding profile of levomepromazine (LMP) in human brain was compared with that of clozapine (CLOZ) and chlorpromazine (CPZ). LMP showed significantly greater binding affinity for both alpha-1 and serotonin-2 binding sites than either CLOZ or CPZ, and significantly greater binding to alpha-2 sites than CPZ. A potent pharmacological effect at these receptor sites may explain the beneficial effect of LMP on psychotic symptoms and akathisia in treatment-resistant schizophrenia recently described in 2 open studies. LMP requires further appraisal as a potentially useful neuroleptic in the management of treatment-resistant schizophrenia.
将左美丙嗪（LMP）在人脑中的受体结合情况与氯氮平（CLOZ）和氯丙嗪（CPZ）进行了比较。LMP对α-1和血清素-2结合位点的结合亲和力显著高于CLOZ或CPZ，且对α-2位点的结合显著高于CPZ。在这些受体位点产生的强效药理作用可能解释了LMP对难治性精神分裂症的精神病性症状和静坐不能的有益作用，这在最近两项开放研究中已有描述。LMP作为难治性精神分裂症治疗中一种潜在有用的抗精神病药物，需要进一步评估。
